Opportunity Information: Apply for PA 16 012
Apply for PA 16 012
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Examination of Survivorship Care Planning Efficacy and Impact (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399,.
- This funding opportunity was created on Oct 23, 2015 and posted on Oct 23, 2015.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Examination of Survivorship Care Planning Efficacy and Impact (R01)" (Funding Opportunity Number PA-16-012) is a National Institutes of Health (NIH) research grant from the U.S. Department of Health and Human Services (Agency listed as HHS-NIH11). It focuses on cancer survivorship and, in particular, on whether survivorship care planning actually improves the real-world outcomes it is often intended to support. The announcement was posted on October 23, 2015, with a closing date of January 7, 2019. It is categorized as a discretionary grant mechanism under an R01, meaning it is aimed at supporting substantial, hypothesis-driven research projects rather than small pilot efforts. The related CFDA numbers are 93.399 (and another listing in the same domain), reflecting NIH program areas tied to cancer-related research and survivorship.
At its core, this funding opportunity is designed to stimulate rigorous research that evaluates the impact of survivorship care planning on cancer survivors after active treatment ends. Survivorship care plans are meant to help patients navigate follow-up care, manage late and long-term effects of therapy, and coordinate between oncology and primary care or other specialty providers. This FOA emphasizes that survivorship care planning should be studied not only as a document or a single clinical task, but as an intervention that could influence behavior, care utilization, and outcomes over time. The overarching purpose is to build stronger evidence about what works, for whom, and under what conditions, so future survivorship interventions can be designed and delivered more effectively.
A major theme of the announcement is evaluating whether care planning improves survivors ability to self-manage late effects of cancer therapy. Late effects can include physical complications, secondary cancers, chronic symptoms, and functional limitations that persist or emerge well after treatment. The FOA also calls attention to adherence-related outcomes, including whether survivorship care planning helps survivors follow medication regimens, keep up with recommended cancer screening, and meet broader health behavior guidelines. These behaviors might include lifestyle practices such as physical activity, tobacco avoidance, nutrition, and other preventive actions that reduce future risk and support overall health.
Another key target is how survivorship care planning influences use of recommended follow-up care. That includes whether survivors receive the right surveillance tests at the right intervals, whether they engage with appropriate specialty follow-up when needed, and whether care planning reduces gaps, fragmentation, or unnecessary services. The FOA also highlights survivor health outcomes and psychosocial outcomes, signaling interest in endpoints such as quality of life, distress, anxiety about recurrence, confidence in managing health, patient satisfaction, and other measures that capture the lived experience of survivorship.
The FOA lays out four specific research aims that applicants are encouraged to address. First, it seeks studies that develop and test metrics for evaluating survivorship care planning. In practice, this means the field needs reliable ways to measure care planning content, quality, delivery processes, patient understanding, and implementation fidelity, along with outcomes attributable to the planning process. Second, it encourages direct evaluation of how survivorship care planning affects morbidity, self-management, adherence to care recommendations, and utilization of follow-up care. This points toward research designs capable of linking care planning to measurable clinical and behavioral outcomes, rather than assuming benefit based on intent alone.
Third, the announcement explicitly invites research on system-level outcomes. This includes analyzing the costs associated with implementing survivorship care planning and understanding its impact on clinicians, care teams, and organizations. In other words, it is not enough to show that a care plan can help patients; researchers are also encouraged to examine what it takes to implement care planning in real clinical settings, what resources are required, how workflows change, and whether the process is sustainable. This systems emphasis also includes interest in organizational-level factors that influence implementation, such as staffing models, electronic health record integration, reimbursement environment, leadership support, and coordination between oncology and primary care.
Fourth, the FOA seeks identification of care models and processes that promote effective survivorship care planning. This opens the door to comparing different approaches, such as who delivers the plan (oncologists, nurses, navigators, primary care clinicians), when it is delivered (end of treatment vs. later transitions), how it is delivered (in-person visits, digital tools, mailed documents, portal-based plans), and how it is integrated into ongoing care. The underlying idea is to move beyond one-size-fits-all planning and toward practical models that can be scaled and adapted across settings while still producing measurable benefit.
Eligibility for this opportunity is broad, reflecting NIH norms for R01 research. Eligible applicants include state, county, and local governments; public and state-controlled and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities; nonprofit organizations with and without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other entities as described in the full eligibility text. This wide eligibility pool supports the FOA goal of encouraging diverse research teams and settings, including academic medical centers, community health systems, and organizations positioned to study survivorship care planning in varied populations and real-world contexts.
The ultimate goal of the FOA is to build a coherent body of scientific evidence that can guide the development and delivery of interventions that improve follow-up care for cancer survivors. Rather than treating survivorship care plans as inherently beneficial, this announcement pushes the field to test effectiveness, clarify mechanisms of action, quantify implementation and cost considerations, and identify models that reliably produce better outcomes. The practical endpoint is knowledge that can inform standards, clinical workflows, and survivorship programs so that care planning becomes not just routine, but demonstrably useful for survivors and feasible for the systems that serve them.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Examination of Survivorship Care Planning Efficacy and Impact (R01)" and the Funding Opportunity Number is PA-16-012.
Which agency is offering this funding opportunity?
This is a National Institutes of Health (NIH) research grant offered by the U.S. Department of Health and Human Services (HHS), with the agency listed as HHS-NIH11.
What type of grant mechanism is this?
This opportunity uses the NIH R01 mechanism. It is described as a discretionary grant and is intended to support substantial, hypothesis-driven research projects rather than small pilot efforts.
What is the main focus of the funding opportunity?
The FOA focuses on cancer survivorship, specifically evaluating whether survivorship care planning improves real-world outcomes for cancer survivors after active treatment ends. It emphasizes studying survivorship care planning as an intervention that may influence behaviors, care utilization, and outcomes over time.
What are survivorship care plans in the context of this FOA?
Survivorship care plans are intended to help patients navigate follow-up care after treatment, manage late and long-term effects of cancer therapy, and support coordination between oncology and primary care or other specialty providers.
What problem is this FOA trying to address?
The FOA is designed to build stronger evidence about whether survivorship care planning actually delivers the benefits it is often expected to provide, including identifying what works, for whom, and under what conditions.
When was the opportunity posted and when does it close?
The announcement was posted on October 23, 2015, and the closing date is January 7, 2019.
What CFDA numbers are associated with this opportunity?
The related CFDA number listed is 93.399 (with another listing in the same domain), reflecting NIH program areas tied to cancer-related research and survivorship.
What kinds of outcomes does the FOA encourage researchers to measure?
The FOA highlights outcomes related to self-management of late effects, adherence to recommended care, use of follow-up services, health outcomes, psychosocial outcomes, and system-level outcomes such as costs and organizational impacts.
What are "late effects" and why are they important to this FOA?
Late effects are physical or functional complications that persist or emerge after cancer treatment, such as chronic symptoms, functional limitations, secondary cancers, or other long-term therapy-related issues. The FOA emphasizes evaluating whether survivorship care planning improves survivors' ability to self-manage these late effects.
What adherence-related outcomes are specifically mentioned?
The FOA calls attention to whether survivorship care planning supports adherence to medication regimens, recommended cancer screening, and broader health behavior guidelines, including lifestyle practices like physical activity, tobacco avoidance, nutrition, and other preventive actions.
How does the FOA approach follow-up care and care utilization?
The FOA encourages research on whether survivorship care planning affects use of recommended follow-up care, such as receiving appropriate surveillance tests at appropriate intervals, engaging in specialty follow-up when needed, and reducing gaps, fragmentation, or unnecessary services.
What psychosocial outcomes are of interest under this FOA?
The FOA signals interest in psychosocial and lived-experience endpoints such as quality of life, distress, anxiety about recurrence, confidence in managing health, patient satisfaction, and similar measures relevant to survivorship.
What are the four specific research aims highlighted in the FOA?
The FOA encourages applicants to address four core areas: (1) develop and test metrics for evaluating survivorship care planning; (2) directly evaluate effects on morbidity, self-management, adherence, and follow-up care utilization; (3) study system-level outcomes such as costs and impacts on clinicians, care teams, and organizations; and (4) identify care models and processes that promote effective survivorship care planning.
What does it mean to "develop and test metrics" for survivorship care planning?
This refers to creating and validating reliable ways to measure survivorship care planning, including care plan content, quality, delivery processes, patient understanding, implementation fidelity, and outcomes that can be attributed to the planning process.
What does the FOA mean by evaluating survivorship care planning as an "intervention"?
The FOA emphasizes that survivorship care planning should not be treated only as a document or a single clinical task. Instead, it should be studied as an intervention that could affect behaviors, healthcare use, and outcomes over time in real-world settings.
What kinds of system-level outcomes does the FOA ask applicants to examine?
The FOA explicitly invites research on costs to implement survivorship care planning and its impact on clinicians, care teams, and organizations. It also points to real-world implementation considerations such as workflows, staffing models, electronic health record integration, reimbursement environment, leadership support, and coordination between oncology and primary care.
What kinds of survivorship care planning models can be studied under this FOA?
The FOA suggests comparing models and processes, including who delivers the plan (oncologists, nurses, navigators, primary care clinicians), when it is delivered (end of treatment versus later transitions), how it is delivered (in-person, digital tools, mailed documents, portal-based plans), and how it is integrated into ongoing care.
Does the FOA favor a one-size-fits-all survivorship care plan approach?
No. The FOA explicitly encourages moving beyond one-size-fits-all planning and toward practical care models that can be scaled and adapted across settings while still producing measurable benefits.
Who is eligible to apply?
Eligibility is broad and includes (among others) state, county, and local governments; public and state-controlled and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities; nonprofit organizations (with and without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and other entities as described in the full eligibility text.
Why is eligibility so broad for this opportunity?
The FOA reflects typical NIH R01 eligibility and supports the goal of encouraging diverse research teams and settings, including academic medical centers, community health systems, and organizations positioned to study survivorship care planning across varied populations and real-world contexts.
What is the ultimate goal of funding research under this FOA?
The goal is to build a coherent body of scientific evidence that can guide survivorship interventions and improve follow-up care for cancer survivors. The FOA pushes researchers to test effectiveness, clarify mechanisms of action, quantify implementation and cost considerations, and identify models that reliably produce better outcomes and are feasible for healthcare systems.
How is this FOA different from treating survivorship care plans as automatically beneficial?
Rather than assuming survivorship care plans are beneficial based on their intent, this FOA prioritizes rigorous evaluation of whether they produce measurable improvements, under what circumstances, and with what implementation requirements and tradeoffs.
Browse more opportunities from the same category: Education, Health
Next opportunity: Rural Health Network Development Planning Program
Previous opportunity: Improving Diabetes Management in Pre-teens, Adolescents and/or Young Adults with Type 1 Diabetes (DP3)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) Apply for PA 16 035 Funding Number: PA 16 035 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R21) Apply for PAR 16 042 Funding Number: PAR 16 042 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (U10) Apply for PAR 16 056 Funding Number: PAR 16 056 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Innovative Questions in Symptom Science and Genomics (R01) Apply for PA 16 024 Funding Number: PA 16 024 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21) Apply for PAR 16 052 Funding Number: PAR 16 052 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $125,000 |
| Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01) Apply for RFA DA 16 011 Funding Number: RFA DA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Questions in Symptom Science and Genomics (R21) Apply for PA 16 023 Funding Number: PA 16 023 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01) Apply for PAR 16 059 Funding Number: PAR 16 059 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01) Apply for PA 16 030 Funding Number: PA 16 030 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Apply for RFA CA 16 001 Funding Number: RFA CA 16 001 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21) Apply for PA 16 029 Funding Number: PA 16 029 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01) Apply for RFA DA 16 014 Funding Number: RFA DA 16 014 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist Award (R50) Apply for PAR 16 025 Funding Number: PAR 16 025 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R01) Apply for PAR 16 041 Funding Number: PAR 16 041 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS High Priority Drug Abuse Research (R01) Apply for PAS 16 018 Funding Number: PAS 16 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 012 Funding Number: RFA DA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
